Results 91 to 100 of about 6,071 (199)

Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29–34 6/7 weeks' gestation in the United States

Pediatrics and Neonatology
Background: Respiratory syncytial virus (RSV) hospitalizations have increased since the 2014 guideline update recommended against the use of palivizumab for preterm infants born ≥29 0/7 weeks' gestational age (GA) without additional risk factors. A novel
Tianzhou Yu, William V. Padula, Leah Yieh, Cynthia L. Gong   +3 more
doaj   +1 more source

Development and validation of an enzyme linked immunosorbent assay for palivizumab serum determination.

, 2013
Palivizumab (Synagis) is a humanized monoclonal antibody (IgG1K) composed of 95 percent human and 5 percent murine sequences. It is directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV).
Ragazzi M., BLOISE, NORA, Montagna M, Avanzini MA, Di Comite A, Iommiello V, VISAI, LIVIA, Stronati M   +7 more
core  

Cost-Effectiveness Analysis of Maternal Respiratory Syncytial Virus Vaccine in Protecting Infants from RSV Infection in Japan

Infectious Diseases and Therapy
Introduction Respiratory syncytial virus (RSV) is one of the major causes of respiratory tract infections among children. Until recently, the monoclonal antibody palivizumab was the only RSV prophylaxis available in Japan.
Naruhiko Ishiwada, Rina Akaishi, Yasuhiro Kobayashi, Kanae Togo, Naohiro Yonemoto, Moe Matsuo, Shinnosuke Kaneko, Amy W. Law, Kazumasa Kamei   +8 more
doaj   +1 more source

Passive immunisation of preterm infants with palivizumab against RSV infection

Palivizumab is a monocloncal antibody used for prevention of respiratory syncytial virus infection. This study reviews the literature regarding evidence of efficacy, safety and cost-effectiveness.
Harkensee C, Brodlie M, Embleton ND, Mckean M   +3 more
core  

MODERN POTENTIALITIES OF IMMUNOPROPHYLAXIS OF SEVERE COURSE OF THE RESPIRATORY SYNCYTIAL VIRAL INFECTION IN CHILDREN WITH THE CONSEQUENCES OF PERINATAL PATHOLOGY

Педиатрическая фармакология, 2011
To a risk group of a heavy course of the respiratory syncytial viral (RSV) infection could be ascribed preterm infants, born before the 35th week of gestation inclusive, as well as children under 2 years old with the bronchopulmonary dysplasia or ...
L.S. Namazova-Baranova, I.V. Davydova, T.V. Turti, I.A. Belyaeva, V.V. Altunin   +4 more
doaj  

Evolución de los recién nacidos con aplicación de palivizumab

"El virus sincitial respiratorio infecta las vías y conductos respiratorios con una incidencia del 90% en pacientes menores de 24 meses, de los cuales 40% desarrollan cuadro de bronquiolitis.
García Fuentes, Yamil Dayri
core  

Reliability of Medicaid Claims Versus Medical Record Data: In a Cost Analysis of Palivizumab

Background: Palivizumab is one of the most costly paediatric medications for Medicaid and other health plans. It is uncertain whether the costs of palivizumab administration are justified in specific risk groups.
John Feaganes, Steven Wegner, Julie Jacobson Vann   +2 more
core  

Efficacy and effectiveness of long-acting monoclonal antibodies and vaccines against RSV: a systematic review and meta-analysis of studies from 2018 to 2025. [PDF]

EClinicalMedicine
Du J, Li S, Hung IFN, Wu JT, Leung K.
europepmc   +1 more source

Palivizumab

medicina, 2002
D, Gupta, P, Gupta
openaire   +3 more sources

Palivizumab prophylaxis and risk of RSV infection among moderate-to-late preterm infants: A nationwide Korean cohort study from 2018 to 2022. [PDF]

Medicine (Baltimore)
So H, Kim Y, Yoon Y, Lee H, Kwon Y, Min J, Kim M, Kim EH, Kim G, Kim YM, Lee B.   +10 more
europepmc   +1 more source